Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Venous Thrombosis 1Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dalteparin 3apixaban 2abelacimab 2MAA868 2isoquercitrin 1edoxaban 1calcium heparin 1bemiparin 1Tinzaparin 1Rivaroxaban 1Nadroparin 1Heparin, Low-Molecular-Weight 1Heparin 1Fondaparinux 1Enoxaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Venous Thrombosis × Nadroparin × Clear all
NCT00312013 2017-03-23

Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer

GlaxoSmithKline

Phase 3 Completed
503 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Venous Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡